P-cadherin, Vimentin and CK14 for identification of basal-like phenotype in breast carcinomas: An immunohistochemical study

Histology and Histopathology

Volumn 25, Issue 8, 2010, Pages 963-974

  Sousa, Bárbara ^a   Paredes, Joana ^a   Milanezi, Fernanda ^a   Lopes, Nair ^a   Martins, Diana ^a   Dufloth, Rozany ^b   Vieira, Daniella ^b   Albergaria, André ^a,c   Veronese, Luiz ^d   Carneiro, Vitor ^e   Carvalho, Sílvia ^a   Costa, José Luis ^a   Zeferino, Luiz ^f   Schmitt, Fernando ^a,g  

^a UNIVERSITY OF PORTO   (Portugal)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^c UNIVERSITY OF MINHO   (Portugal)

^d General Hospital of UNIMED   (Brazil)

^e HOSPITAL DO DIVINO ESPÍRITO SANTO   (Portugal)

^f UNIVERSITY OF CAMPINAS   (Brazil)

^g University of Porto   (Portugal)

Author keywords

Basal like breast cancer; CK14; P cadherin; Vimentin

Indexed keywords

CADHERIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; VIMENTIN;

ARTICLE; BREAST TUMOR; CARCINOMA; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; PHENOTYPE;

BREAST NEOPLASMS; CADHERINS; CARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; PHENOTYPE; RECEPTOR, ERBB-2; VIMENTIN;

EID: 77956895496     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. Abd El-Rehim D. M., Ball G., Pinder S. E., Rakha E., Paish C., Robertson J. F., Macmillan D., Blamey R. W. and Ellis I. O. (2005). Highthroughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int. J. Cancer 116, 340-350.
2. Abd El-Rehim D. M., Pinder S. E., Paish C. E., Bell J., Blamey R. W., Robertson J. F., Nicholson R. I. and Ellis I. O. (2004). Expression of luminal and basal cytokeratins in human breast carcinoma. J. Pathol. 203, 661-671.
3. Arnes J. B., Brunet J. S., Stefansson I., Begin L. R., Wong N., Chappuis P. O., Akslen L. A. and Foulkes W. D. (2005). Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin. Cancer Res. 11, 4003-4011.
4. Banerjee S., Reis-Filho J. S., Ashley S., Steele D., Ashworth A., Lakhani S. R. and Smith I. E. (2006). Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J. Clin. Pathol. 59, 729-735.
5. Bertucci F., Finetti P., Cervera N., Esterni B., Hermitte F., Viens P. and Birnbaum D. (2008). How basal are triple-negative breast cancers? Int. J. Cancer 123, 236-240.
6. Cheang M. C., Voduc D., Bajdik C., Leung S., McKinney S., Chia S. K., Perou C. M. and Nielsen T. O. (2008). Basal-like breast cancer defined by five biomarkers has superior prognostic value than triplenegative phenotype. Clin. Cancer Res. 14, 1368-1376.
7. Collett K., Stefansson I. M., Eide J., Braaten A., Wang H., Eide G. E., Thoresen S. O., Foulkes W. D. and Akslen L. A. (2005). A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol. Biomarkers Prev. 14, 1108-1112.
8. Dent R., Trudeau M., Pritchard K. I., Hanna W. M., Kahn H. K., Sawka C. A., Lickley L. A., Rawlinson E., Sun P. and Narod S. A. (2007). Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 13, 4429-4434.
9. Diaz L. K., Cryns V. L., Symmans W. F. and Sneige N. (2007). Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv. Anat. Pathol. 14, 419-430.
10. Domagala W., Lasota J., Bartkowiak J., Weber K. and Osborn M. (1990a). Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction. Am. J. Pathol. 136, 219-227.
11. Domagala W., Lasota J., Dukowicz A., Markiewski M., Striker G., Weber K. and Osborn M. (1990b). Vimentin expression appears to be associated with poor prognosis in node-negative ductal NOS breast carcinomas. Am. J. Pathol. 137, 1299-1304.
12. Fan C., Oh D. S., Wessels L., Weigelt B., Nuyten D. S., Nobel A. B., van't Veer L. J. and Perou C. M. (2006). Concordance among geneexpression-based predictors for breast cancer. N. Engl. J. Med. 355, 560-569.
13. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M. and Boyle P. (2007). Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 18, 581-592.
14. Foulkes W. D., Brunet J. S., Stefansson I. M., Straume O., Chappuis P. O., Begin L. R., Hamel N., Goffin J. R., Wong N., Trudel M., Kapusta L., Porter P. and Akslen L. A. (2004). The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascularproliferation+) phenotype of BRCA1-related breast cancer. Cancer Res. 64, 830-835.
15. Fulford L. G., Easton D. F., Reis-Filho J. S., Sofronis A., Gillett C. E., Lakhani S. R. and Hanby A. (2006). Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 49, 22-34.
16. Fulford L. G., Reis-Filho J. S., Ryder K., Jones C., Gillett C. E., Hanby A., Easton D. and Lakhani S. R. (2007). Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res. 9, R4.
17. Gamallo C., Moreno-Bueno G., Sarrio D., Calero F., Hardisson D. and Palacios J. (2001). The prognostic significance of P-cadherin in infiltrating ductal breast carcinoma. Mod. Pathol. 14, 650-654.
18. Hennessy B. T., Gonzalez-Angulo A. M., Stemke-Hale K., Gilcrease M. Z., Krishnamurthy S., Lee J. S., Fridlyand J., Sahin A., Agarwal R., Joy C., Liu W., Stivers D., Baggerly K., Carey M., Lluch A., Monteagudo C., He X., Weigman V., Fan C., Palazzo J., Hortobagyi G. N., Nolden L. K., Wang N. J., Valero V., Gray J. W., Perou C. M. and Mills G. B. (2009). Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 69, 4116-4124.
19. Herschkowitz J. I., Simin K., Weigman V. J., Mikaelian I., Usary J., Hu Z., Rasmussen K. E., Jones L. P., Assefnia S., Chandrasekharan S., Backlund M. G., Yin Y., Khramtsov A. I., Bastein R., Quackenbush J., Glazer R. I., Brown P. H., Green J. E., Kopelovich L., Furth P. A., Palazzo J. P., Olopade O. I., Bernard P. S., Churchill G. A., Van Dyke T. and Perou C. M. (2007). Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 8, R76.
20. Honeth G., Bendahl P. O., Ringner M., Saal L. H., Gruvberger-Saal S. K., Lovgren K., Grabau D., Ferno M., Borg A. and Hegardt C. (2008). The CD44+/CD24-phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 10, R53.
21. Hu Z., Fan C., Oh D. S., Marron J. S., He X., Qaqish B. F., Livasy C., Carey L. A., Reynolds E., Dressler L., Nobel A., Parker J., Ewend M. G., Sawyer L. R., Wu J., Liu Y., Nanda R., Tretiakova M., Ruiz Orrico A., Dreher D., Palazzo J. P., Perreard L., Nelson E., Mone M., Hansen H., Mullins M., Quackenbush J. F., Ellis M. J., Olopade O. I., Bernard P. S. and Perou C. M. (2006). The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7, 96.
22. Jones C., Nonni A. V., Fulford L., Merrett S., Chaggar R., Eusebi V. and Lakhani S. R. (2001). CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation. Br. J. Cancer 85, 422-427.
23. Jones C., Ford E., Gillett C., Ryder K., Merrett S., Reis-Filho J. S., Fulford L. G., Hanby A. and Lakhani S. R. (2004). Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes. Clin. Cancer Res. 10, 5988-5997.
24. Kim M. J., Ro J. Y., Ahn S. H., Kim H. H., Kim S. B. and Gong G. (2006). Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neuoverexpressing phenotypes. Hum. Pathol. 37, 1217-26.
25. Korsching E., Packeisen J., Liedtke C., Hungermann D., Wulfing P., van Diest P. J., Brandt B., Boecker W. and Buerger H. (2005). The origin of vimentin expression in invasive breast cancer: epithelialmesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? J. Pathol. 206, 451-7.
26. Koutselini H., Markopoulos C., Lambropoulou S., Gogas H., Kandaraki C. and Gogas J. (1995). Relationship of epidermal growth factor receptor (EGFR), proliferating cell nuclear antigen (PCNA) and vimentin expression and various prognostic factors in breast cancer patients. Cytopathology 6, 14-21.
27. Kovacs A. and Walker R. A. (2003). P-cadherin as a marker in the differential diagnosis of breast lesions. J. Clin. Pathol. 56, 139-141.
28. Kreike B., van Kouwenhove M., Horlings H., Weigelt B., Peterse H., Bartelink H. and van de Vijver M. J. (2007). Gene expression profiling and histopathological characterization of triplenegative/basal-like breast carcinomas. Breast Cancer Res. 9, R65.
29. Kusinska R., Potemski P., Jesionek-Kupnicka D. and Kordek R. (2005). Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma-relation with grade, stage, estrogen receptor and HER2. Pol. J. Pathol. 56, 107-110.
30. Laakso M., Loman N., Borg A. and Isola J. (2005). Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod. Pathol. 18, 1321-1328.
31. Laakso M., Tanner M., Nilsson J., Wiklund T., Erikstein B., Kellokumpu-Lehtinen P., Malmstrom P., Wilking N., Bergh J. and Isola J. (2006). Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin. Cancer Res. 12, 4185-4191.
32. Liu H., Fan Q., Zhang Z., Li X., Yu H. and Meng F. (2008). Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers. Hum. Pathol. 39, 167-74.
33. Livasy C. A., Karaca G., Nanda R., Tretiakova M. S., Olopade O. I., Moore D. T. and Perou C. M. (2006). Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod. Pathol. 19, 264-271.
34. Matos I., Dufloth R., Alvarenga M., Zeferino L. C. and Schmitt F. (2005). p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch. 447, 688-694.
35. Milanezi F., Carvalho S. and Schmitt F. C. (2008). EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy. Expert Rev. Mol. Diagn. 8, 417-434.
36. Morris G. J., Naidu S., Topham A. K., Guiles F., Xu Y., McCue P., Schwartz G. F., Park P. K., Rosenberg A. L., Brill K. and Mitchell E. P. (2007). Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a singleinstitution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 110, 876-884.
37. Nielsen T. O., Hsu F. D., Jensen K., Cheang M., Karaca G., Hu Z., Hernandez-Boussard T., Livasy C., Cowan D., Dressler L., Akslen L. A., Ragaz J., Gown A. M., Gilks C. B., van de Rijn M. and Perou C. M. (2004). Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 10, 5367-5374.
38. Palacios J., Benito N., Pizarro A., Suarez A., Espada J., Cano A. and Gamallo C. (1995). Anomalous expression of P-cadherin in breast carcinoma. Correlation with E-cadherin expression and pathological features. Am. J. Pathol. 146, 605-612.
39. Paredes J., Albergaria A., Oliveira J. T., Jeronimo C., Milanezi F. and Schmitt F. C. (2005). P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin. Cancer Res. 11, 5869-5877.
40. Paredes J., Correia A. L., Ribeiro A. S., Albergaria A., Milanezi F. and Schmitt F. C. (2007a). P-cadherin expression in breast cancer: a review. Breast Cancer Res. 9, 214.
41. Paredes J., Lopes N., Milanezi F. and Schmitt F. C. (2007b). P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ. Virchows Arch. 450, 73-80.
42. Paredes J., Milanezi F., Viegas L., Amendoeira I. and Schmitt F. (2002). P-cadherin expression is associated with high-grade ductal carcinoma in situ of the breast. Virchows Arch. 440, 16-21.
43. Peralta Soler A., Knudsen K. A., Salazar H., Han A. C. and Keshgegian A. A. (1999). P-cadherin expression in breast carcinoma indicates poor survival. Cancer 86, 1263-1272.
44. Perou C. M., Sorlie T., Eisen M. B., van de Rijn M., Jeffrey S. S., Rees C. A., Pollack J. R., Ross D. T., Johnsen H., Akslen L. A., Fluge O., Pergamenschikov A., Williams C., Zhu S. X., Lonning P. E., Borresen-Dale A. L., Brown P. O. and Botstein D. (2000). Molecular portraits of human breast tumours. Nature 406, 747-752.
45. Potemski P., Kusinska R., Watala C., Pluciennik E., Bednarek A. K. and Kordek R. (2005). Prognostic relevance of basal cytokeratin expression in operable breast cancer. Oncology 69, 478-485.
46. Rakha E. A. and Ellis I. O. (2009). Triple-negative/basal-like breast cancer: review. Pathology 41, 40-47.
47. Rakha E. A., El-Rehim D. A., Paish C., Green A. R., Lee A. H., Robertson J. F., Blamey R. W., Macmillan D. and Ellis I. O. (2006a). Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur. J. Cancer 42, 3149-3156.
48. Rakha E. A., Putti T. C., Abd El-Rehim D. M., Paish C., Green A. R., Powe D. G., Lee A. H., Robertson J. F. and Ellis I. O. (2006b). Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J. Pathol. 208, 495-506.
49. Rakha E. A., El-Sayed M. E., Green A. R., Lee A. H., Robertson J. F. and Ellis I. O. (2007a). Prognostic markers in triple-negative breast cancer. Cancer 109, 25-32.
50. Rakha E. A., El-Sayed M. E., Green A. R., Paish E. C., Lee A. H. and Ellis I. O. (2007b). Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology 50, 434-438.
51. Rakha E. A., Tan D. S., Foulkes W. D., Ellis I. O., Tutt A., Nielsen T. O. and Reis-Filho J. S. (2007c). Are triple-negative tumours and basal-like breast cancer synonymous? Breast Cancer Res. 9, 404; author reply 405.
52. Rakha E. A., Elsheikh S. E., Aleskandarany M. A., Habashi H. O., Green A. R., Powe D. G., El-Sayed M. E., Benhasouna A., Brunet J. S., Akslen L. A., Evans A. J., Blamey R., Reis-Filho J. S., Foulkes W. D. and Ellis I. O. (2009). Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin. Cancer Res. 15, 2302-23, 10.
53. Rakha E. A., Reis-Filho J. S. and Ellis I. O. (2008). Basal-like breast cancer: a critical review. J. Clin. Oncol. 26, 2568-2581.
54. Raymond W. A. and Leong A. S. (1989). Vimentin-a new prognostic parameter in breast carcinoma? J. Pathol. 158, 107-114.
55. Reis-Filho J. S. (2005). Re: Korsching et al. The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? J. Pathol. 2005;206:451-457.
56. J. Pathol. 207, 367-9; author reply 370-1.
57. Reis-Filho J. S. and Tutt A. N. (2008). Triple negative tumours: a critical review. Histopathology 52, 108-118.
58. Reis-Filho J. S., Milanezi F., Paredes J., Silva P., Pereira E. M., Maeda S. A., de Carvalho L. V. and Schmitt F. C. (2003). Novel and classic myoepithelial/stem cell markers in metaplastic carcinomas of the breast. Appl. Immunohistochem. Mol. Morphol. 11, 1-8.
59. Reis-Filho J. S., Milanezi F., Carvalho S., Simpson P. T., Steele D., Savage K., Lambros M. B., Pereira E. M., Nesland J. M., Lakhani S. R. and Schmitt F. C. (2005). Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res. 7, R1028-1035.
60. Reis-Filho J. S., Milanezi F., Steele D., Savage K., Simpson P. T., Nesland J. M., Pereira E. M., Lakhani S. R. and Schmitt F. C. (2006). Metaplastic breast carcinomas are basal-like tumours. Histopathology 49, 10-21.
61. Ricardo S. A., Milanezi F., Carvalho S. T., Leitao D. R. and Schmitt F. C. (2007). HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas. J. Clin. Pathol. 60, 1001-1005.
62. Rodriguez-Pinilla S. M., Sarrio D., Honrado E., Hardisson D., Calero F., Benitez J. and Palacios J. (2006). Prognostic significance of basallike phenotype and fascin expression in node-negative invasive breast carcinomas. Clin. Cancer Res. 12, 1533-1539.
63. Rodriguez-Pinilla S. M., Sarrio D., Honrado E., Moreno-Bueno G., Hardisson D., Calero F., Benitez J. and Palacios J. (2007). Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. J. Clin. Pathol. 60, 1006-1012.
64. Santini D., Ceccarelli C., Taffurelli M., Pileri S. and Marrano D. (1996). Differentiation pathways in primary invasive breast carcinoma as suggested by intermediate filament and biopathological marker expression. J. Pathol. 179, 386-391.
65. Siziopikou K. P. and Cobleigh M. (2007). The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast 16, 104-107.
66. Sorlie T., Perou C. M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M. B., van de Rijn M., Jeffrey S. S., Thorsen T., Quist H., Matese J. C., Brown P. O., Botstein D., Eystein Lonning P. and Borresen-Dale A. L. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 98, 10869-10874.
67. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J. S., Nobel A., Deng S., Johnsen H., Pesich R., Geisler S., Demeter J., Perou C. M., Lonning P. E., Brown P. O., Borresen-Dale A. L. and Botstein D. (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA 100, 8418-8423.
68. Sotiriou C., Neo S. Y., McShane L. M., Korn E. L., Long P. M., Jazaeri A., Martiat P., Fox S. B., Harris A. L. and Liu E. T. (2003). Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl. Acad. Sci. USA 100, 10393-10398.
69. Spitale A., Mazzola P., Soldini D., Mazzucchelli L. and Bordoni A. (2008). Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann. Oncol. 20, 628-635.
70. Tamimi R. M., Baer H. J., Marotti J., Galan M., Galaburda L., Fu Y., Deitz A. C., Connolly J. L., Schnitt S. J., Colditz G. A. and Collins L. C. (2008). Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res. 10, R67.
71. Tan D. S., Marchio C., Jones R. L., Savage K., Smith I. E., Dowsett M. and Reis-Filho J. S. (2008). Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat. 111, 27-44.
72. Tang P., Wang J. and Bourne P. (2008). Molecular classifications of breast carcinoma with similar terminology and different definitions: are they the same? Hum. Pathol. 39, 506-513.
73. Thomas P. A., Kirschmann D. A., Cerhan J. R., Folberg R., Seftor E. A., Sellers T. A. and Hendrix M. J. (1999). Association between keratin and vimentin expression, malignant phenotype, and survival in postmenopausal breast cancer patients. Clin. Cancer Res. 5, 2698-2703.
74. Tischkowitz M., Brunet J. S., Begin L. R., Huntsman D. G., Cheang M. C., Akslen L. A., Nielsen T. O. and Foulkes W. D. (2007). Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 7, 134.
75. Tsuda H., Takarabe T., Hasegawa F., Fukutomi T. and Hirohashi S. (2000). Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am. J. Surg. Pathol. 24, 197-202.
76. Turner N. C., Reis-Filho J. S., Russell A. M., Springall R. J., Ryder K., Steele D., Savage K., Gillett C. E., Schmitt F. C., Ashworth A. and Tutt A. N. (2007). BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26, 2126-2132.
77. van de Rijn M., Perou C. M., Tibshirani R., Haas P., Kallioniemi O., Kononen J., Torhorst J., Sauter G., Zuber M., Kochli O. R., Mross F., Dieterich H., Seitz R., Ross D., Botstein D. and Brown P. (2002). Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am. J. Pathol. 161, 1991-1996.
78. van't Veer L. J., Dai H., van de Vijver M. J., He Y. D., Hart A. A., Mao M., Peterse H. L., van der Kooy K., Marton M. J., Witteveen A. T., Schreiber G. J., Kerkhoven R. M., Roberts C., Linsley P. S., Bernards R. and Friend S. H. (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536.